Natural Alternatives International, Inc. Announces New Sustained Release Beta-Alanine Intellectual Property

   Natural Alternatives International, Inc. Announces New Sustained Release
                      Beta-Alanine Intellectual Property

PR Newswire

SAN MARCOS, Calif., Nov. 6, 2012

SAN MARCOS, Calif., Nov. 6, 2012 /PRNewswire/ -- Natural Alternatives
International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer
and marketer of customized nutritional supplements, announced today that the
U.S. Patent and Trademark Office has issued a Notice of Allowance of its
patent application directed to sustained release formulations of beta-alanine.
This Notice follows the September 14, 2012, issuance of NAI's corresponding
sustained release patent in Canada and a similar Notice of Allowance in South
Korea. This new intellectual property becomes part of NAI's growing portfolio
covering its CarnoSyn^® beta-alanine and SR CarnoSyn^® product.

Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is very
excited by the addition of this new intellectual property related to a broad
range of sustained release formulations for beta-alanine compositions. We
believe this new patented technology will dramatically expand the use of
beta-alanine to a much broader group of consumers. These new patent rights
will not expire until 2028, and further demonstrates our commitment and
significant investment in the CarnoSyn^® beta-alanine business."

Dr. Roger Harris, a named inventor on NAI's new sustained release intellectual
property, added, "The use of extended release formulations for beta-alanine is
an advancement in supplement intake. The result is an increase in the
beneficial amount of beta-alanine retained in the body while reducing loss
through metabolic processes. Additionally, sustained release formulations
minimize or reduce parasthesia, a common side effect that can be experienced
by those taking beta-alanine as an individual amino acid." Using sustained
release forms of beta-alanine will not only meet the needs of bodybuilders,
but also expand into other areas of use by individuals.

Since 2008, over 30 peer-reviewed studies have been published related to
beta-alanine supplementation. Thirteen of these studies were directed to
sustained release forms of beta-alanine, eight of which were published in 2012

Initially, NAI intends to launch a sustained release beta-alanine product in
tablet form. It will be exclusively manufactured by NAI at its facilities in
Vista, CA and sold by its exclusively licensed distributor, Compound
Solutions, Inc., ("CSI"), a science and marketing based distributor of raw
materials to the sports nutrition, dietary supplement, food, pharmaceutical
and personal care industries. NAI intends to expand its offering of various
sustained release delivery systems into other forms such as pills, capsules,
gel tabs, chewable tablets and powder. NAI also plans to work with companies
to develop and manufacture customized formulations covered by its intellectual

NAI, headquartered in San Marcos, California, is a leading formulator,
manufacturer and marketer of nutritional supplements and provides strategic
partnering services to its customers. NAI's comprehensive partnership approach
offers a wide range of innovative nutritional products and services to NAI's
clients including: scientific research, clinical studies, proprietary
ingredients, customer-specific nutritional product formulation, product
testing and evaluation, marketing management and support, packaging and
delivery system design, regulatory review and international product
registration assistance. For more information about NAI, please see its
website at

This press release contains forward-looking statements within the meaning of
applicable securities laws that are not historical facts and information.
These statements represent our intentions, expectations and beliefs concerning
future events, including, among other things, our expectations and beliefs
with respect to our future financial and operating results, the outcome of
pending litigation, the continued validity of our patents, and our ability to
successfully develop, license and enforce our intellectual property rights. We
wish to caution readers these statements involve risks and uncertainties that
could cause actual results and outcomes for future periods to differ
materially from any forward-looking statement or views expressed herein. NAI's
financial performance and the forward-looking statements contained herein are
further qualified by other risks including those set forth from time to time
in the documents filed by us with the Securities and Exchange Commission,
including our most recent Annual Report on Form 10-K and Quarterly Report on
Form 10-Q.

CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural
Alternatives International, Inc., at 760-736-7700 or

Web site:

SOURCE Natural Alternatives International, Inc.

Press spacebar to pause and continue. Press esc to stop.